2026-01-19 - Analysis Report
**Amgen (AMGN) Financial Report**
================================

**Company Overview**
-------------------

Amgen - 글로벌 바이오 테크놀로지 선도 제약사

**Return Rate Comparison**
-------------------------

- Cumulative return of review stock (AMGN): 28.18%
- Cumulative return of comparison stock (S&P 500, VOO): 82.54%
- Divergence: N/A
- Relative divergence: N/A
- The comparison stock (S&P 500, VOO) has a significantly higher cumulative return than the review stock (AMGN).

**Alpha, Beta Analysis**
----------------------

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 5.0% | 8.5% | 5.0% | 1.1 | 104.8B |
| 2017-2019  | 25.0% | 9.1% | 16.0% | 0.9 | 129.8B |
| 2018-2020  | 17.0% | 13.1% | -4.0% | 0.8 | 123.8B |
| 2019-2021  | 10.0% | 19.4% | -28.0% | 0.8 | 121.1B |
| 2020-2022  | 8.0% | 19.4% | -2.0% | 0.6 | 141.4B |
| 2021-2023  | 15.0% | 19.4% | -2.0% | 0.4 | 155.1B |
| 2022-2024  | 19.0% | 18.4% | -7.0% | 0.4 | 140.3B |
| 2023-2025  | 6.0% | 18.4% | -43.0% | 0.5 | 176.2B |

**Recent Stock Price Fluctuations**
---------------------------------

- Close: $330.41
- 5-day SMA: $327.85
- 20-day SMA: $329.14
- 60-day SMA: $324.51

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence**
----------------------------------------------------------------

- Market Risk Indicator (MRI): 0.80
- RSI: 47.80
- PPO: -0.04
- Hybrid Signal: Buy (Cash 20%)
- Risk Level: Medium (MRI 0.80)
- Recent (20 days) relative divergence change: 0.0
- 7-day Rank change: 0
- 7-day Dynamic Expected Return change: 0.0

**Recent News & Significant Events**
-----------------------------------

* Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 80% of the company.
* DISCO Oncology Pact And MariTide Obesity Data Might Change The Case For Investing In Amgen (AMGN).
* Sequoia Financial Advisors LLC Has $45.33 Million Position in Amgen Inc. $AMGN.
* Stocks making the biggest moves midday: Deckers Outdoor, Amgen, Western Digital, Ventyx Biosciences & more.
* Amgen Stock (AMGN) Falls despite Obesity Drug Update — Here’s Wall Street’s Take.
* BofA Securities raises Amgen stock price target to $304 on valuation shift.

**Analyst Opinions**
---------------------

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.34 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 331.59 / 425.00 / 180.00

**Recent Earnings Analysis**
---------------------------

| Date | EPS | Revenue |
|---|---: |---:|
| 2025-11-05 | 5.98 | 9.56 B$ |
| 2025-08-06 | 2.66 | 9.18 B$ |
| 2025-05-02 | 3.22 | 8.15 B$ |
| 2024-10-31 | 5.27 | 8.50 B$ |

**Revenue and Profitability**
---------------------------

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

**Capital and Profitability**
---------------------------

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

**Comprehensive Analysis**
-------------------------

Based on the provided data, Amgen (AMGN) has a lower return rate compared to the S&P 500 (VOO). The company's cumulative return is 28.18%, while the comparison stock has a cumulative return of 82.54%. Additionally, Amgen's stock price has experienced fluctuations in recent days, with a closing price of $330.41.

According to the Alpha, Beta analysis, Amgen's CAGR and MDD have varied significantly across different time periods, indicating volatility in the company's performance. The hybrid signal is Buy (Cash 20%) with a medium risk level, and the recent relative divergence change is 0.0.

In terms of earnings analysis, Amgen's EPS and revenue have fluctuated in recent quarters. The company's profit margin and ROE have also varied across different quarters, indicating changes in profitability.

Considering the recent news and significant events, institutional shareholders own 80% of the company, and there have been changes in analyst opinions, with a Buy key and a mean score of 2.34 (~Buy).

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.